section name header

Pronunciation ⬇

ka-FEEN SI-trate

Classifications ⬆ ⬇

Therapeutic Classification: central nervous system stimulants

Pharmacologic Classification: respiratory stimulants

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Increases levels of cyclic AMP by inhibiting phosphodiesterase.
  • Acts as a bronchial smooth muscle relaxant.
  • Suggested mechanisms of action include:
    • Stimulation of the respiratory center,
    • Increased minute ventilation,
    • Decreased threshold to hypercapnea,
    • Increased response to hypercapnea,
    • Increased skeletal muscle tone,
    • Decreased diaphragmatic fatigue,
    • Increased metabolic rate,
    • Increased oxygen consumption.
Therapeutic effects:
  • Decrease in periods of apnea.

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability; also absorbed after oral administration.

Distribution: Rapidly distributes to the brain; CSF levels in neonates are similar to plasma levels.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP1A2 isoenzyme; 3–8% converted to theophylline.

Half-Life: Infants >9 mo, Children, and Adults: 5 hr; Neonates: 3–4 days.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
IVrapidend of infusion24 hr
POrapid30 min–2 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: tachycardia

Derm: dry skin, rash, skin breakdown

Endo: hyperglycemia, hypoglycemia

GI: GI bleeding, feeding intolerance, gastritis, NECROTIZING ENTEROCOLITIS

GU: increased urine output

MS: muscle tremors, twitches

Neuro: insomnia, irritability, jitteriness, restlessness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Cafcit